Abstract
Ursodeoxycholic acid (UDCA) is a non-toxic, hydrophilic bile acid in widespread clinical use mainly for acute and chronic liver disease. Recently, treatment with UDCA in hepatic graft-ver-sus-host disease has been given in immunosuppressive therapy for improvement of the biochemical markers of cholestasis. Moreover, it has been reported that UDCA possesses immunomodulatory effects by the suppression of cytokine production. In the present study, we hypothesized that UDCA may inhibit the production of the pro-inflammatory cytokine, IL-1β, and nitric oxide (NO) in microglia. In the study, we found that 100 μg/mL UDCA effectively inhibited these two pro-inflammatory factors at 24 h and 48 h, compared to the Ap42-pre-treated groups. These results were compared with the LPS+UDCA group to confirm the UDCA effect. As microglia can be activated by several stimulants, such as Aβ42, in Alzheimers brain and can release those inflammatory factors, the ability to inhibit or at least decrease the production of IL-1β and NO in Alzheimers disease (AD) is essential. Using RT-PCR, ELISA and the Griess Reagent System, we therefore found that UDCA in Aβ42 pre-treated cultures played a significant role in suppressing the expression or the production of IL-1β and NO. Similarly, lipopolysaccharide (LPS) did not activate microglia in the presence of UDCA. Moreover, we found that UDCA exhibits a prolonged effect on microglial cells (up to 48 h), which suggests that UDCA may play an important role in chronic cell damage due to this long effect. These results further imply that UDCA could be an important cue in suppressing the microglial activation stimulated by massive Aâ peptides in the AD progressing brain.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Banati, R. B., Gehrmann, J., Schubert, P., and Kreutzberg, G. W., Cytotoxicity of microglia.Glia, 7, 111–118 (1996).
Bayer, T. A., Wirths, O., Majtenyl, K., Hartmann, T., Multhaup, G., Beyreuther, K., and Czech, C., Key factors in Alzheimer’s disease: β-amyloid precursor protein processing, metabolism, and intraneuronal transport.Brain Pathology, 11, 1–11 (2001).
Benveniste, E. N., Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action.Am. J. Physiol., 263, C1–16 (1992).
Beuers, U., Boyer, J. L., and Paumgartner, G., Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications.Hepatology, 28, 1449–1453 (1998).
Chao, C. C., Hu, S., Molitor, T. W., Shaskan, E. C., and Peterson, P. K., Activated microglia mediated neuronal cell injury via a nitric oxide mechanism.J. Immunol., 149, 2736–2741 (1992).
Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H., and Brosnan, C., Microglia and cytokines in neurological disease, with special REFERENCe to AIDS and Alzheimer’s disease. [Review].Glia, 7, 75–83. (1993).
Forloni, G., Demichelli, F., Giorgi, S., Bendotti, C., and Angeretti, N., Expression of amyloid precursor protein mRNAs in endothelial, neuronal, and glial cell: modulation by interleukin-1.Brain. Res., 16, 128–134 (1992).
Giulian, D., Ameboid microglia as effectors of inflammation in the central nervous system.J. Neuroscience. Res., 18, 155–171 (1987).
Giulian, D., Baker, T. J., Shih, L., and Lachman, L. B., Interleukin-1 of the central nervous system is produced by ameboid microglia.J. Exp. Med., 164, 594 (1986).
Hirano, F., Tanaka, H., Makino, Y., Okamoto, K., and Makino, I., Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression.J. Gastroenterol., 31 (1), 55–60 (1996).
Invernizzi, P., Salzman, A. L., Szabo, C., Ueta, I., O’Connor, M., and Setchell, K. D., Ursodeoxycholate inhibits induction of NOS in human intestinal epithelial cells an.in vivo.Am. J. Physiol., 273, G131–138 (1997).
Jaffrey, S. R. and Snyder, S. H., Nitric oxide: a neural messenger.Annu. Rev. Cell. Dev., 11, 417–440 (1995).
Joo, S. S., Chang, J. K., Park, J. H., Kang, H. C., and Lee, D. I., Immuno activation of lectin-conjugated praecoxin A on IL-6, IL-12 expression.Arch. Pharm. Res., 25, 954–963 (2002).
Kim, S. H., Won, S. J., Sohn, S. H., Kwon, H. J., Lee, J. Y., Park, J. H., and Gwag, B. J., Brain-derived neurotrophic factor can act as a pronecrotic factor through transcriptional and translocational activation of NADPH oxidase.J. Cell Biol., 159, 821–831 (2002).
Kim, W. G., Mohney, R. P., Wilson, B., Heohn, G. H., Liu, B., and Hong, J. S., Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia.J. Neurosci., 20, 6309–6316 (2000).
Liu, L., Sakaguchi, T., Cui, X., Shirai, Y., Nishimaki, T., and Hatakeyama, K., Liver regeneration enhanced by orally administered ursodesoxycholic acid is mediated by immunosuppression in partially hepatectomized rats.Am. J. Chin. Med., 30 (1), 119–126 (2002).
Lue, L., Rydel, R., Brigham, E. F., Yang, L., Hampek, H., Murphy, G. M., Brachova, L., Yan, S., Walker, D. G., Shen, Y., and Rogers, J., Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microgli.in vitro.Glia, 35, 72–79 (2001).
Lue, L. R and Walker, D. G., Modeling Alzheimer’s disease immune therapy mechanisms; interaction of human postmortem microglia with antibody- opsonized amyloid beta peptide.J. Neurosci. Res. 70 (4), 599–610 (2002).
Mrak, R. E., Sheng, J. G., and Griffin, W. S. T., Glial cytokines in Alzheimers disease: review and pathogenic implication.Hum. Pathol., 26, 816–823 (1995).
Paresce, D. M., Chung, H., and Maxfield, Slow degration of aggregates of the Alzheimers disease amyloid beta-protein by microglial cell.J. Biol. Chem., 272, 29390–29397 (1997).
Paumgartner, G. and Beuers, U., Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.Perspectives In Clinical Hepatology, 525–530 (2002).
Possel, H., Noack, H., Putzke, J., Wolf, G., and Sies, H., Selective upregulation of inducible Nitric Oxide Synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia.Glia, 32, 51–59 (2000).
Rodrigues, C. M. P., Ma, X., Kren, B. T., and Streer, C. J., A novel role for ursodeoxycholic acid in inhibiting apotosis by modulating mitochondrial membrane perturbation.J. Clin. Invest., 101 (12), 2790–2799 (1998).
Selkoe, D. J., The molecular pathology of Alzheimer’s disease. [Review.Neuron, 6, 487–498 (1991).
Shoda, M., Uber die Ursodeoxycholsaure aus Barengallen und ihre physiologische Wirkung.J. Biochem., 7, 505–517 (1927).
Strijbos, P. J. and Rothwell, N. J., Interleukin-1beta attenuates excitatory amino acid-induced neurodegenerstio.in vitro: involvement of nerve growth factor.J. Neurosci., 153, 3468–3474 (1995).
Varadarajan, S., Yatin, S., Aksenova, M., and Butterfield, D. A., Review: Alzheimers amyloid beta-peptide associated free radical oxidative stress and neurotoxicity.J. Structural Biol., 130, 184–208 (2000).
Webster, S. D., Park, M., Fonseca, M. I., and Tenner, A. J., Structural and functional evidence for microglial expression of C1qRP, the C1q receptor that enhances phagocytosis.J. Leukocyte Biology, 67, 109–116 (2000).
Yoshikawa, M., Tsujii, T., Matsumura, K., Yamao, J., Matsumura, Y., Kubo, R., Fukui, H., and Ishizaka, S., Immunomodulatory effects of ursodeoxycholic acid on immune responses.Hepatology, 16 (2), 358–364 (1992).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joo, SS., Kang, HC., Won, TJ. et al. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1β and nitric oxide in rat microglia. Arch Pharm Res 26, 1067–1073 (2003). https://doi.org/10.1007/BF02994760
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02994760